SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1285<i>I thought you were smarter than that. for the Genentech Ovarian Cancer DewDiligence_on_SI-6/5/2007
1284Hey I thought you were smarter than that for the Genentech Ovarian Cancer study silversurfer2007-6/5/2007
1283<i>Article mentions bowel perforations for Avastin at 11%. I don't remDewDiligence_on_SI-6/5/2007
1282This abstract from last year indicates the very serious side affects of Avastin silversurfer2007-6/5/2007
1281<i>bowel perforations for Avastin at 11%</i> Yes that is correct - Biomaven-6/5/2007
1280Regeneron Stumbles on Mediocre Data Evelyn M. Rusli, 06.04.07, 7:30 PM ET Forbeskenhott-6/5/2007
1279Even if it is equal to Lucentis, I would rather be poked in the eye once a monthrumorbuster-5/17/2007
1278Thanks Doc for the disclosure..I agree with Miljenko..I'd be surprised if tzeta1961-5/17/2007
1277Still it is, if nothing more than at least equal to Lucentis. However, it will bMiljenko Zuanic-5/17/2007
1276Appreciate you sharing that, Praveen. (I don't have any.)keokalani'nui-5/17/2007
1275Coz I found out REGN isn't as ground breaking as GTCB:-) My main basis is Vdr.praveen-5/17/2007
1274What happened to your conviction that VEGF-Trap was a great candidate for AMD?DewDiligence_on_SI-5/17/2007
1273Got out of REGN early today coz of the rumours that ASCO data isn't good. I dr.praveen-5/17/2007
1272When will this company stop with controversy (laying)? Latest from MS, SchleifeMiljenko Zuanic-5/5/2007
1271Free and bound VEGF level, after B. REGN never disclose true numbers from their Miljenko Zuanic-4/30/2007
1270Late breaker oral presentation at AACR: <i>Abstract Number: LB-184 PresenBiomaven-4/17/2007
1269NEJM article today on use of an IL-1 antagonist (AMGN's anakinra) in type IIBiomaven-4/11/2007
1268CoMentis Initiates Phase-2 Trial for AMD Eye-Drop Therapy: investorshub.comDewDiligence_on_SI-4/10/2007
1267We will see the 5 arm data at ARVO in early May.Think of it this way. VEGF trap dr.praveen-4/2/2007
1266Hello Biomaven and rkrw- I was wrong regarding the royalties on sales for anyBiotech Jim-4/1/2007
1265<i>I am very interested in the antibodies that are about to enter the clinBiomaven-3/30/2007
1264PR says mid single digit royalties, same as the azn pr I believe. Would like to rkrw-3/30/2007
1263This is the second such deal, AstraZeneca was the first and was reported a few mBiotech Jim-3/30/2007
1262Indeed, few more of this license and they will secure nice cash flow for next 3-Miljenko Zuanic-3/30/2007
1261That's significant - $80 million real dollars, not biobucks, plus potentialBiomaven-3/30/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News